Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605994 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT01605994 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 115 participants.
The verdict
NCT01605994, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
Includes a placebo-controlled sequential, ascending multiple-dose panels (10 panels, 8 ascending doses, and 2 fixed Japanese Panels exploring safety, tolerability, and Pharmacokinetic (PK) measures
Interventions
- DRUG BMS-933043
- DRUG Placebo matching with BMS-933043
- DRUG Antacid Buffer Predose Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605994
The ClinicalTrials.gov registry entry for NCT01605994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-933043 is the first listed.
NCT01605994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605994 about?
NCT01605994 is a clinical study titled "Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects". Includes a placebo-controlled sequential, ascending multiple-dose panels (10 panels, 8 ascending doses, and 2 fixed Japanese Panels exploring safety, tolerability, and Pharmacokinetic (PK) measures
What is the current status of trial NCT01605994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2012-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01605994?
The interventions under investigation include: BMS-933043 (DRUG), Placebo matching with BMS-933043 (DRUG), Antacid Buffer Predose Solution (DRUG).
Who is sponsoring clinical trial NCT01605994?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.